Global law firm Greenberg Traurig, P.A. advised APx Acquisition Corp. I, a special purpose acquisition company, in its definitive business combination agreement with OmnigenicsAI Corp, a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd, a UK-based AI-enabled preventive medicine company.

The strategic combination will create a global AI-driven genomics company with a significant presence in Latin America that will focus on providing secure, precise, and reliable biological data. The combined company currently operates primarily in Argentina, Mexico, Paraguay, and the UK, though it is expected to continue expanding its geographic footprint beyond Latin America, including into the United States.

Upon closing, OmnigenicsAI Corp will become the shareholder of APx and MultiplAI. The shares and warrants of OmnigenicsAI Corp will be listed on Nasdaq under the ticker symbols “OMNI” and “OMNIW,” respectively. The transaction is expected to close mid-year and values OmnigenicsAI Corp and MultiplAI at a combined enterprise value of $340 million.